Updated daily
Drug recalls
Every FDA drug recall since 2004 - 18,109 enforcement reports, newest first, with what was recalled, why, the lots and the company. Class I is the most serious.
Class IITerminatedJun 10, 2020Dextroamphetamine SaccharateSome bottles may contain mixed strengths of the product.Teva Pharmaceuticals USA · D-1285-2020Class IITerminatedJun 10, 2020Estriol USP Micronized 5 GFailed impurities/ degradation specifications: Out of specification for organic impurities.Triova Pharmaceuticals LLC · D-1284-2020Class IIITerminatedJun 3, 2020Lamotrigine TabletsPresence of Foreign Substance visually consistent with the silica granules present in the desiccant packs utilized during storage of the product.Jubilant Cadista Pharmaceuticals, Inc. · D-1281-2020Class IIOngoingJun 3, 2020Maximum Strength Lidocaine Cold & Hot PatchCGMP Deviations: due to the loss of product manufacturing records and retain product samples, there is no assurance that the product will remain within specification...Wuhan Bingbing Pharmaceutical Co., Ltd. · D-1280-2020Class IIOngoingJun 3, 2020MencaineCGMP Deviations: due to the loss of product manufacturing records and retain product samples, there is no assurance that the product will remain within specification...Wuhan Bingbing Pharmaceutical Co., Ltd. · D-1279-2020Class IIOngoingJun 3, 2020LidoProCGMP Deviations: due to the loss of product manufacturing records and retain product samples, there is no assurance that the product will remain within specification...Wuhan Bingbing Pharmaceutical Co., Ltd. · D-1278-2020Class IIOngoingJun 3, 2020LidoPatchCGMP Deviations: due to the loss of product manufacturing records and retain product samples, there is no assurance that the product will remain within specification...Wuhan Bingbing Pharmaceutical Co., Ltd. · D-1277-2020Class IITerminatedJun 3, 2020Doxycycline Hyclate tablets USPFailed dissolution specificationsPD-Rx Pharmaceuticals, Inc. · D-1276-2020Class IITerminatedJun 3, 2020Doxycycline Hyclate Tablets USPFailed dissolution specification: The dissolution test at the 24 month time point (end of shelf life) yielded an out of specification result.West-Ward Columbus Inc · D-1274-2020Class IIITerminatedMay 27, 2020Ethacrynic Acid Tablets USPFailed Impurities/Degradation Specifications: Out of Specification for impurity 6 and total degradants.West-Ward Columbus Inc · D-1282-2020Class IIITerminatedMay 27, 2020Gabapentin Tablets USPFailed Impurities/Degradation Specifications; failure of Impurity A test at the 12-month long-term stability testing.InvaGen Pharmaceuticals, Inc. · D-1272-2020Class IITerminatedMay 27, 2020AloprimDiscoloration: Out-of-specification results for appearance obtained during routine stability testing at the end of shelf-life for the parameters Appearance and Color of...Mylan Institutional LLC · D-1271-2020Class ITerminatedMay 27, 2020LACTATED RINGER'S InjectionPresence of Particulate Matter: confirmed customer complaint for the presence of particulate matter identified as iron oxide.ICU Medical Inc · D-1270-2020Class ITerminatedMay 20, 2020Finasteride Plus 1.25 mg CapsuleCross Contamination with Other Products; Finasteride Plus 1.25mg capsules were found to contain minoxidil.MasterPharm LLC · D-1269-2020Class IIITerminatedMay 20, 2020ChapStick Total Hydration Moisture + Tint + SPF15 Pretty in Pink Net Wt. 0.08 OZLabeling: Not elsewhere classified: Observed separation in the secondary packaging in the blister and the backer cardGlaxosmithkline Consumer Healthcare Holdings · D-1268-2020Class IIITerminatedMay 20, 2020ChapStick Total Hydration Moisture + Tint + SPF15 Very Berry Net Wt. 0.08 OZLabeling: Not elsewhere classified: Observed separation in the secondary packaging in the blister and the backer cardGlaxosmithkline Consumer Healthcare Holdings · D-1267-2020Class IIITerminatedMay 20, 2020ChapStick Total Hydration Moisture + Tint + SPF15 Peachy Keen Net Wt. 0.08 OZLabeling: Not elsewhere classified: Observed separation in the secondary packaging in the blister and the backer cardGlaxosmithkline Consumer Healthcare Holdings · D-1266-2020Class IIITerminatedMay 20, 2020Memantine Hydrochloride Extended-Release CapsulesFailed dissolution specifications: Low stage 3 results obtained for dissolution during routine stability testing.The Harvard Drug Group · D-1262-2020Class IITerminatedMay 13, 2020Epinephrine Injection USPCGMP Deviations: Precautions taken due to Out-of-specification for trigger force for a non-marketed lot number that shares the same component.Teva Pharmaceuticals USA · D-1260-2020Class IITerminatedMay 13, 2020Infuvite PEDiatric PharmacyDefective Container: Sub-optimal crimping in vial of Pediatric Infuvite Multiple VitaminsSandoz, Inc · D-1259-2020Class ITerminatedMay 6, 2020Ceftazidime for Injection USP and Dextrose for Injection USPFailed Stability Specifications: Out-of-Specification (OOS) results for High Molecular Weight Polymers.B. Braun Medical Inc · D-1257-2020Class IIITerminatedMay 6, 2020Esomeprazole Magnesium Delayed Release Capsules USPDiscoloration: product contains brown pelletsDr. Reddy's Laboratories, Inc. · D-1256-2020Class IITerminatedMay 6, 2020Nizatidine Oral SolutionCGMP Deviations: potential N-Nitrosodimethylamine (NDMA) amounts above levels established by the FDA.Amneal Pharmaceuticals of New York, LLC · D-1253-2020Class IITerminatedApr 29, 2020Cefixime for Oral Suspension USPSubpotent Drug: low out of specification (OOS) test result observed in long term stability study.Lupin Pharmaceuticals Inc. · D-1252-2020Class IITerminatedApr 29, 2020PEPPERMINT LIP MOISTURIZERSuperpotent drug: This lot of SPF containing lip balm contains up to 150% of the label claim for active ingredient Oxybenzone.Yusef Manufacturing Laboratories, LLC · D-1251-2020Class IITerminatedApr 29, 2020Lisinopril Tablets USPProduct Mix-Up: a complaint received indicating mix-up of 10 mg Lisinopril tablets inside of 2 sealed bottles of 20 mg/1000 count bottles.Lupin Pharmaceuticals Inc. · D-1250-2020Class IITerminatedApr 29, 2020DaytranaDefective Delivery System: Out of specification for mechanical peel and shear.Noven Therapeutics, LLC · D-1249-2020Class IITerminatedApr 29, 2020DaytranaDefective Delivery System: Out of specification for mechanical peel and shear.Noven Therapeutics, LLC · D-1248-2020Class IITerminatedApr 29, 2020DaytranaDefective Delivery System: Out of specification for mechanical peel and shear.Noven Therapeutics, LLC · D-1247-2020Class IITerminatedApr 22, 2020Acetaminophen and Codeine Phosphate 300/30 mg tabletcGMP DeviationsH J Harkins Company Inc dba Pharma Pac · D-1246-2020Class IITerminatedApr 22, 2020EstradiolcGMP deviations: Presence of foreign material (Teflon)introduced at the production level.B & B Pharmaceuticals, Inc. · D-1244-2020Class IITerminatedApr 22, 2020DermatoneMicrobial contamination of non-sterile products: positive test for yeast and bacteria.Filltech USA, LLC · D-1242-2020Class IITerminatedApr 22, 2020DermatoneMicrobial contamination of non-sterile products: positive test for yeast and bacteria.Filltech USA, LLC · D-1241-2020Class IITerminatedApr 22, 2020Losartan Potassium TabletsCGMP Deviations: Impurity for N-nitroso-N-methyl-4-aminobutryric Acid (NBMA) detected in active ingredient (API) used to manufacture finished products.Golden State Medical Supply Inc. · D-1238-2020Class IITerminatedApr 22, 2020Oxycodone and Acetaminophen TabletsCGMP Deviations: Products were manufactured in a processing area in which water leakage was observedAurobindo Pharma USA Inc. · D-1237-2020Class IITerminatedApr 22, 2020Phentermine Hydrochloride CapsulesCGMP Deviations: Products were manufactured in a processing area in which water leakage was observedAurobindo Pharma USA Inc. · D-1236-2020Class IITerminatedApr 22, 2020Mirtazapine TabletsCGMP Deviations: Products were manufactured in a processing area in which water leakage was observedAurobindo Pharma USA Inc. · D-1235-2020Class IITerminatedApr 22, 2020Simvastatin TabletsCGMP Deviations: Products were manufactured in a processing area in which water leakage was observedAurobindo Pharma USA Inc. · D-1234-2020Class IITerminatedApr 22, 2020Levetiracetam Tablets USP 750 mgCGMP Deviations: Products were manufactured in a processing area in which water leakage was observedAurobindo Pharma USA Inc. · D-1233-2020Class IITerminatedApr 22, 2020Gabapentin CapsulesCGMP Deviations: Products were manufactured in a processing area in which water leakage was observedAurobindo Pharma USA Inc. · D-1232-2020